BeiGene to Present at Upcoming Investor Conferences
March 05 2018 - 7:00AM
BeiGene, Ltd. (NASDAQ:BGNE), a commercial-stage biopharmaceutical
company focused on developing and commercializing innovative
molecularly targeted and immuno-oncology drugs for the treatment of
cancer, today announced that the company will present at two
upcoming investor conferences:
- The Cowen and Company 38th Annual Health Care Conference in
Boston on Monday, March 12, at 2:10 p.m. (ET); and
- The Barclays Global Healthcare Conference 2018 in Miami on
Wednesday, March 14, at 4:20 p.m. (ET).
Live webcasts can be accessed from the investors section of
BeiGene’s website at http://ir.beigene.com/ and archived replays
will be available for 90 days following each event.
About BeiGene
BeiGene is a global, commercial-stage, research-based
biotechnology company focused on molecularly targeted and
immuno-oncology cancer therapeutics. With a team of over 900
employees in China, the United States, and Australia, BeiGene is
advancing a pipeline consisting of novel oral small molecules and
monoclonal antibodies for cancer. BeiGene is also working to create
combination solutions aimed to have both a meaningful and lasting
impact on cancer patients. BeiGene markets ABRAXANE® (nanoparticle
albumin–bound paclitaxel), REVLIMID® (lenalidomide), and VIDAZA®
(azacitidine) in China under a license from Celgene
Corporation.i
Investor
Contact
Lucy Li, Ph.D.+1 781-801-1800ir@beigene.com
Media Contact
Liza Heapes+ 1 857-302-5663media@beigene.com
____________________
i ABRAXANE®, REVLIMID®, and VIDAZA® are registered trademarks of
Celgene Corporation.
BeiGene (NASDAQ:BGNE)
Historical Stock Chart
From Mar 2024 to Apr 2024
BeiGene (NASDAQ:BGNE)
Historical Stock Chart
From Apr 2023 to Apr 2024